
DMAC Stock Forecast & Price Target
DMAC Analyst Ratings
Bulls say
DiaMedica Therapeutics Inc. is positioned for significant revenue growth, with probability-adjusted projections indicating revenues from its lead product candidate DM199 could escalate from $11.1 million in 2027 to $212.4 million by 2036, driven by its applications in acute ischemic stroke and preeclampsia. The company's ongoing Phase 2 clinical programs are bolstered by successful early-stage results, which may highlight the safety and efficacy of DM199, reducing risks associated with ischemic stroke treatments. Additionally, enhancements in the manufacturing process for DM199 support scalable production, aligning with the promising outcomes anticipated from its clinical trials and potential market expansion.
Bears say
DiaMedica Therapeutics has reported a net loss of $6.1 million or $0.15 per diluted share for the third quarter of 2024, indicating significant financial strains. There are considerable risks associated with its developmental candidates DM199 and DM300, including the potential failure to achieve projected peak commercial revenues due to market dynamics and the ability to secure necessary capital resources for ongoing operations. Furthermore, challenges in protecting intellectual property may hinder the company's competitive position in the biopharmaceutical sector, exacerbating concerns about its long-term viability.
This aggregate rating is based on analysts' research of DiaMedica Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
DMAC Analyst Forecast & Price Prediction
Start investing in DMAC
Order type
Buy in
Order amount
Est. shares
0 shares